Synthroid and Testosterone Interaction: What to Know Before Combining These Medications

Why This Interaction Matters Clinically

Hypothyroidism and hypogonadism overlap more often than most patients expect. A 2018 cross-sectional analysis of U.S. Men aged 40 to 69 in NHANES found that subclinical hypothyroidism (TSH 4.5 to 10 mIU/L) was present in roughly 4.3% of the male population, and up to 38.7% of men over 45 may have testosterone levels below 300 ng/dL according to data from the Hypogonadism in Males (HIM) study (N=2,162) 1. That creates a large pool of men on both levothyroxine and testosterone replacement therapy (TRT) simultaneously.

The Binding Globulin Shift

The primary pharmacokinetic interaction runs through thyroxine-binding globulin. TBG carries approximately 70% of circulating T4. Exogenous testosterone accelerates hepatic TBG clearance, reducing total T4 and total T3 concentrations without necessarily changing free hormone levels in a stable patient 2. The clinical risk: a provider who monitors only total T4 (instead of free T4 and TSH) may incorrectly interpret the drop as worsening hypothyroidism and raise the levothyroxine dose.

When Free Hormone Levels Do Shift

In some patients, the TBG reduction is large enough that free T4 rises transiently before the hypothalamic-pituitary-thyroid (HPT) axis compensates. A small prospective study of 14 hypogonadal men starting testosterone cypionate 200 mg every two weeks found free T4 increased by a mean of 0.3 ng/dL at week 4, returning to baseline by week 12 3. That transient rise can trigger palpitations, anxiety, or tremor in patients already on a full-replacement levothyroxine dose.

The bottom line: free T4 and TSH (not total T4) are the correct monitoring targets whenever testosterone is added, changed, or stopped.

Pharmacodynamic Overlap: Lipids and Erythropoiesis

Beyond binding-protein pharmacokinetics, levothyroxine and testosterone share two pharmacodynamic domains that warrant co-monitoring. Neither drug "blocks" the other, but their combined metabolic effects can push lab values outside safe ranges faster than either drug alone.

Lipid Metabolism

Levothyroxine lowers LDL cholesterol by upregulating hepatic LDL receptors. Hypothyroid patients who reach euthyroid TSH levels on Synthroid typically see LDL fall by 10 to 30 mg/dL 4. Testosterone, by contrast, tends to lower HDL by 5 to 15% while LDL effects are variable. A meta-analysis of 30 RCTs (N=1,642 men on TRT) published in The Journal of Clinical Endocrinology & Metabolism found a mean HDL decrease of 0.49 mmol/L with injectable testosterone 5.

For the patient on both drugs, the net lipid picture depends on the balance between levothyroxine's LDL-lowering action and testosterone's HDL-lowering tendency. A fasting lipid panel at baseline, 3 months, and 12 months is a reasonable schedule, consistent with the Endocrine Society's 2018 guideline on testosterone therapy in men with hypogonadism 6.

Erythropoiesis and Polycythemia Risk

Testosterone stimulates erythropoietin production and directly activates erythroid progenitor cells. The TTrials (Testosterone Trials, N=788) showed a mean hemoglobin increase of 1.0 g/dL in men over 65 receiving transdermal testosterone gel versus placebo over 12 months 7. Levothyroxine, while not a classic erythropoietic agent, corrects the mild normocytic anemia of hypothyroidism. A patient moving from hypothyroid and hypogonadal to euthyroid and eugonadal may see hemoglobin climb by 2 to 3 g/dL from both drugs combined.

The FDA-approved labeling for testosterone cypionate injection states that hematocrit should be checked at baseline, at 3 to 6 months, and annually thereafter, with a threshold to withhold therapy if hematocrit exceeds 54% 8. That threshold applies regardless of whether levothyroxine is co-prescribed, but clinicians should be aware that correcting hypothyroidism simultaneously can accelerate the hematocrit rise.

CYP Enzyme and Transporter Considerations

Levothyroxine is not meaningfully metabolized by cytochrome P450 enzymes. Its primary routes of elimination are deiodination (by type I, II, and III deiodinases), conjugation (glucuronidation and sulfation in the liver), and fecal excretion of unabsorbed drug 9.

Does Testosterone Affect Levothyroxine Absorption?

No direct evidence supports a testosterone effect on levothyroxine GI absorption. Levothyroxine is absorbed primarily in the jejunum and upper ileum, and its absorption is impaired by co-ingestion with calcium, iron, PPIs, and certain foods. Testosterone (injectable, transdermal, or oral) does not share these absorption pathways.

Glucuronidation Overlap

Both testosterone and T4 undergo hepatic glucuronidation via UGT (UDP-glucuronosyltransferase) enzymes. Theoretically, high-dose testosterone could compete for UGT2B7 or UGT1A1 capacity, but no published human pharmacokinetic study has demonstrated a clinically meaningful change in levothyroxine clearance from this mechanism. The interaction is classified as theoretical, not established 10.

In clinical terms, the CYP/transporter interaction between these two drugs is negligible. The interaction that matters is the TBG-mediated shift described above and the pharmacodynamic overlap in lipids and hematocrit.

Dose Adjustment Protocols

Starting testosterone in a patient already stable on levothyroxine rarely demands an immediate levothyroxine dose change. The correct approach is watchful monitoring.

Recommended Monitoring Timeline

1. Baseline (before testosterone initiation): TSH, free T4, CBC with differential, fasting lipid panel, PSA (men over 40).
2. Week 6 to 8 after testosterone start: TSH and free T4. If TSH is suppressed below 0.4 mIU/L with elevated free T4, consider reducing levothyroxine by 12.5 to 25 mcg.
3. Month 3: Hematocrit, lipid panel, total and free testosterone (trough level for injectables).
4. Month 6: Repeat TSH, free T4, hematocrit.
5. Annually thereafter: TSH, free T4, CBC, lipid panel, comprehensive metabolic panel.

When to Reduce Levothyroxine

A levothyroxine dose reduction is indicated if TSH drops below the reference range and the patient reports hyperthyroid symptoms (resting heart rate above 100, heat intolerance, unintentional weight loss, tremor). The typical reduction is one tablet strength down: for example, from 100 mcg to 88 mcg, or from 75 mcg to 50 mcg. Do not reduce the dose based on a single lab draw if the patient is asymptomatic; confirm with a repeat TSH at 4 to 6 weeks.

When to Hold Testosterone

Per the Endocrine Society's 2018 guideline, testosterone should be held or the dose reduced if hematocrit exceeds 54%, regardless of symptom status, because of the associated thromboembolic risk 6. Therapeutic phlebotomy is an option for patients who cannot tolerate dose reduction. The guideline also recommends against initiating TRT in men with hematocrit above 48% without close monitoring.

Cardiovascular Safety of the Combination

The question of cardiovascular safety with TRT gained clarity from the TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-Term Vascular Events and Efficacy Response in Hypogonadal Men, N=5,204), published in The New England Journal of Medicine in 2023. TRAVERSE found that transdermal testosterone was noninferior to placebo for major adverse cardiovascular events (MACE) over a mean follow-up of 33 months (hazard ratio 0.99; 95% CI, 0.81 to 1.21) 11.

Thyroid Status as a Modifier

Uncontrolled hypothyroidism independently raises cardiovascular risk through elevated LDL, diastolic hypertension, and accelerated atherosclerosis. A population-based cohort study from Denmark (N=563,700) found that TSH above 10 mIU/L was associated with a hazard ratio of 1.89 for ischemic heart disease 12. Ensuring stable euthyroid status with levothyroxine before or concurrent with TRT initiation is therefore not merely a drug-interaction concern. It is a cardiovascular risk management strategy.

Practical Guidance

For patients on both medications, the American Thyroid Association (ATA) 2014 guideline recommends maintaining TSH within the reference range (typically 0.45 to 4.12 mIU/L) and re-evaluating any time a new medication is added that could alter thyroid hormone binding or metabolism 13. The Endocrine Society TRT guideline recommends annual cardiovascular risk factor assessment including blood pressure, fasting glucose, HbA1c, and lipids 6.

Special Populations

Transgender Men on Testosterone

Transgender men (female-to-male) on testosterone who also require levothyroxine face the same TBG-lowering interaction. Estrogen has the opposite effect on TBG (raising it), so the pre-transition TBG level may be higher, making the drop after testosterone initiation more pronounced. TSH and free T4 should be rechecked at 6 to 8 weeks and again at 6 months after starting testosterone as part of gender-affirming hormone therapy 14.

Older Adults

Men over 65 have both a higher prevalence of subclinical hypothyroidism and a higher baseline cardiovascular risk. The TRUST trial (Thyroid Hormone Replacement for Subclinical Hypothyroidism, N=737, mean age 74.4) found no benefit of levothyroxine for symptoms or quality of life when TSH was between 4.6 and 19.9 mIU/L 15. In this age group, the decision to co-prescribe both medications deserves a thorough risk-benefit discussion addressing polycythemia risk, falls risk from overreplacement, and the uncertain symptomatic benefit of treating mild TSH elevations.

Women on Low-Dose Testosterone

Some women receive low-dose testosterone (typically 5 to 10 mg transdermal cream daily) for hypoactive sexual desire disorder. At these physiologic female doses, the effect on TBG is minimal, and clinically significant levothyroxine interaction is unlikely. Monitoring TSH at the next routine thyroid check (usually 6 to 12 months) is sufficient.

Patient Counseling Points

Patients starting both medications, or adding one to the other, should understand four things.

First, keep taking levothyroxine the same way: on an empty stomach, 30 to 60 minutes before breakfast, separated from calcium and iron supplements by at least 4 hours. Testosterone (injectable, gel, or patch) does not need to be separated in time from levothyroxine.

Second, report symptoms of thyroid overreplacement promptly. Rapid heartbeat, excessive sweating, unexplained weight loss, or tremor may indicate that the levothyroxine dose needs to come down after testosterone is started.

Third, do not skip lab appointments. The 6-to-8-week TSH recheck after any testosterone dose change is the single most important safety step for this combination.

Fourth, stay hydrated and report headaches or visual changes. These can be early signs of polycythemia, particularly in the first 6 months of TRT.

Hematocrit above 54% requires immediate clinical action, including temporary testosterone discontinuation and possible therapeutic phlebotomy 6.